AN2 Therapeutics (ANTX) officer tax-related sale of 327 shares disclosed

Rhea-AI Filing Summary

AN2 Therapeutics principal accounting officer Sarah Joanne Williams sold 327 shares of common stock at $1.06 per share. The March 3, 2026 open‑market sale was made under grant terms to satisfy tax withholding from Restricted Stock Units vesting on February 28, 2026. After this transaction she directly holds 66,848 shares, and her holdings include multiple RSU awards that vest in installments through future years, subject to her continued service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Williams Sarah Joanne

(Last) (First) (Middle)

C/O AN2 THERAPEUTICS, INC.

1300 EL CAMINO REAL, SUITE 100

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AN2 Therapeutics, Inc. [ ANTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		S		327(1)	D	$1.06	66,848(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on February 28, 2026.

2. Includes (a) 48,375 RSUs which vest as follows: 1/4th of the shares vests in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2026, and the balance of (b) 10,938 RSUs which vest as follows: 1/4th of the RSUs vests in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2025, and (c) 11,850 RSUs which vest as follows: 1/16th of the RSUs vests in substantially equal installments quarterly (rounded down to the nearest whole number of shares) over four years from May 28, 2024, in each case subject to the Reporting Person's continuous service through each applicable vesting date. A total of 3,501 shares from the aggregate number of the RSUs issued under (b) and (c) above were sold to cover taxes and a total of 814 shares were sold on the open market.

Remarks:

Exhibits:

	/s/ Sarah Joanne Williams	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did AN2 Therapeutics (ANTX) report for Sarah Joanne Williams?

AN2 Therapeutics reported that Principal Accounting Officer Sarah Joanne Williams sold 327 shares of common stock. The sale occurred on March 3, 2026, in an open-market transaction at $1.06 per share, primarily to cover tax withholding from recently vested Restricted Stock Units.

How many AN2 Therapeutics (ANTX) shares did Sarah Joanne Williams sell and at what price?

She sold 327 shares of AN2 Therapeutics common stock at $1.06 per share. This open-market sale was relatively small and was executed in connection with tax withholding obligations arising from the vesting of Restricted Stock Units on February 28, 2026.

Why did Sarah Joanne Williams sell AN2 Therapeutics (ANTX) shares in this Form 4 filing?

The shares were sold pursuant to the terms of her equity grant to satisfy tax withholding obligations. These obligations arose when certain Restricted Stock Units vested on February 28, 2026, so the transaction reflects tax-related selling rather than a discretionary reduction of her overall equity position.

How many AN2 Therapeutics (ANTX) shares does Sarah Joanne Williams own after the sale?

After the March 3, 2026 transaction, she directly owns 66,848 shares of AN2 Therapeutics common stock. Her equity position also includes several RSU awards that vest over four years from January 1, 2026, January 1, 2025, and May 28, 2024, subject to continued service.

What Restricted Stock Unit grants does Sarah Joanne Williams hold at AN2 Therapeutics (ANTX)?

Her holdings include 48,375 RSUs vesting annually over four years from January 1, 2026; 10,938 RSUs vesting annually over four years from January 1, 2025; and 11,850 RSUs vesting quarterly over four years from May 28, 2024, all contingent on continued service.

Do AN2 Therapeutics (ANTX) footnotes explain prior share sales by Sarah Joanne Williams?

Yes. The footnotes state that 3,501 shares from certain RSU grants were previously sold to cover taxes and 814 shares were sold on the open market. These details clarify that portions of her sales activity relate to tax obligations from RSU vesting rather than purely discretionary selling.